Credit: Kimberly Boyles/Adobe Stock

Payments made to U.S. doctors suggest an influence campaign by Novo Nordisk to promote its weight-loss drugs Wegovy and Saxenda, an investigative report by Reuters has found. The analysis showed that Novo spent approximately $26 million in payments to physicians in the U.S., with that number certain to be higher if another weight-loss drug, Ozempic, were included.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Broker Regulation
Health Care Reform
Employer-Paid